Literature DB >> 12051959

Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding.

D F Horrobin1, K Jenkins, C N Bennett, W W Christie.   

Abstract

Much of the literature on omega-3 and omega-6 fatty acids suggests that desirable effects of omega-3 fatty acids are in part related to depletion of arachidonic acid (AA). However, in rats and humans, we have found that low doses of EPA actually elevate membrane AA phospholipid concentrations. In patients with schizophrenia, treatment with eicosapentaenoic acid (EPA) produced clinical improvement, but that improvement was greater at a dose of 2 g/day than at 4 g/day. The improvement was not significantly correlated with changes in either EPA or docosahexaenoic acid (DHA) but was highly significantly positively correlated with rises in red cell membrane AA. We suggest that elevation of concentrations of both AA and EPA in cell membranes may be important for health. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051959     DOI: 10.1054/plef.2001.0338

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  13 in total

1.  Structural insight into the differential effects of omega-3 and omega-6 fatty acids on the production of Abeta peptides and amyloid plaques.

Authors:  Zareen Amtul; Markus Uhrig; Richard F Rozmahel; Konrad Beyreuther
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 2.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

Review 3.  Polyunsaturated fatty acid supplementation for schizophrenia.

Authors:  C B Joy; R Mumby-Croft; L A Joy
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 4.  Clinical potential of omega-3 fatty acids in the treatment of schizophrenia.

Authors:  Robin Emsley; Piet Oosthuizen; Susan J van Rensburg
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population.

Authors:  Maria Hedelin; Marie Löf; Marita Olsson; Tommy Lewander; Björn Nilsson; Christina M Hultman; Elisabete Weiderpass
Journal:  BMC Psychiatry       Date:  2010-05-26       Impact factor: 3.630

6.  Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia.

Authors:  Susan J van Rensburg; Cornelius M Smuts; Dinie Hon; Martin Kidd; Sulene van der Merwe; Christo Myburgh; Piet Oosthuizen; Robin Emsley
Journal:  Metab Brain Dis       Date:  2009-10-14       Impact factor: 3.584

Review 7.  Cognition, dopamine and bioactive lipids in schizophrenia.

Authors:  Ruth Condray; Jeffrey K Yao
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

8.  Arachidonic acid drives postnatal neurogenesis and elicits a beneficial effect on prepulse inhibition, a biological trait of psychiatric illnesses.

Authors:  Motoko Maekawa; Noriko Takashima; Miho Matsumata; Shiro Ikegami; Masanori Kontani; Yoshinobu Hara; Hiroshi Kawashima; Yuji Owada; Yoshinobu Kiso; Takeo Yoshikawa; Kaoru Inokuchi; Noriko Osumi
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

Review 9.  Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

Authors:  Brian M Ross; Jennifer Seguin; Lee E Sieswerda
Journal:  Lipids Health Dis       Date:  2007-09-18       Impact factor: 3.876

10.  The role of background diet on the effects of eicosapentaenoic acid and docosahexaenoic acid supplementation in healthy pre-menopausal women: a randomized, cross-over, controlled study.

Authors:  Megan Arnold Gomes; Xiaoyuan Jia; Iris Kolenski; Alison M Duncan; Kelly A Meckling
Journal:  Lipids Health Dis       Date:  2016-09-29       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.